Atopic dermatitis and psoriasis news - Medizinonline

The microsite is supported by AbbVie.

As a global, research-driven biopharmaceutical company, AbbVie is committed to treating serious, mostly chronic diseases. Research and innovation are the foundation of the company’s operations. Therapeutic areas include dermatology.

Highlights

Interview with Prof. Thomas Kündig (USZ) and Prof. Diego Kyburz (USB)

“You have to stop treating psoriasis as just a skin disease”.

Chronic inflammatory dermatoses

Highlights from the AAD Congress 2022

CME Atopic Dermatitis

State-of-the-Art of Targeted Immunotherapy for Adult Atopic Dermatitis.

Video contributions

This content is machine translated Video Tutorial

Management of a new targeted treatment in atopic dermatitis.

Professional article

This content is machine translated Sponsored Content: Interdisciplinary training event

New Horizons: Knowledge to the power of three (6. February 2025)

Practical knowledge networking, recognizing connections, understanding immune-mediated chronic inflammatory diseases and interdisciplinary treatment. Take part in New Horizons: knowledge to the power of three.

This content is machine translated Sponsored Content: Inflammatory skin diseases

“New horizons” in the treatment of inflammatory skin diseases

The field of inflammatory skin diseases is constantly evolving. Updates on current standard treatments, innovative therapy options and artificial intelligence were presented at two accredited live webinars entitled “New Horizons in Dermatology” in June 2024. Below you will find a summary of the most important concepts presented.

This content is machine translated Sponsored Content: Cumulative Life Course Impairment (CLCI)

The burden of psoriasis gets under your skin

Psoriasis is a complex chronic disease that can go beyond skin lesions and affect various aspects of life. The underlying inflammation, which can lead to a variety of concomitant diseases, plays a decisive role [1-3]. Early systemic treatment may show promise for achieving complete skin improvement as well as reducing inflammation and potential comorbidities [4-5].

This content is machine translated Sponsored Content: Atopic dermatitis: Roadshow 2024

Better standard of care through joint decision-making

The first Swiss Atopic Dermatitis (AD) Roadshow took place at the beginning of February 2024. AD expert Prof. Jonathan Silverberg from the George Washington University School of Medicine and Health Sciences in Washington, DC, USA, spoke at five Swiss centers about the various systemic AD treatments. The focus was on individualized patient-centered therapy to raise the standard of care for AD. In the post-Roadshow interview, Prof. Silverberg shares his experiences and thoughts on shared decision-making and the Minimal Disease Activity (MDA) concept.

This content is machine translated Atopic Dermatitis Roadshow | February 5 – 8 | Jonathan Silverberg

Is good still good enough for you and your AD patients? Raising the standard of treatment for atopic dermatitis

We are pleased to invite you to our roadshow on atopic dermatitis (AD). The roadshow will take place from February 5 to 8, 2024 with the expert Professor Jonathan Silverberg (George Washington University, Washington, DC, USA).

This content is machine translated SGDV Congress 2023: Psoriasis and atopic dermatitis

On the trail with Sherlock Holmes and CSI – Mystery cases solved

At the “somewhat different” AbbVie Symposium at this year’s Swiss Dermatology Congress (SGDV Congress) in Lausanne, experts did some excellent detective work: a missing person was found and the mysteriously altered behavior of a patient was also clarified. Find out here how Sherlock Holmes and the CSI agent were able to solve the cases at the symposium.

This content is machine translated medizinonline

Long-term data on upadacitinib show a consistent safety profile and no new safety signals [1].

This content is machine translated Atopic dermatitis

Achieving high treatment goals with the Minimal Disease Activity concept

Patients with moderate to severe atopic dermatitis suffer from the physical and psychological effects of the disease and yet do not receive adequate treatment with systemic therapies, or often only after a delay [1-3]. The Minimal Disease Activity approach aims to consistently identify patients who are candidates for advanced treatment, combining the treat-to-target concept with shared decision-making between patients and physicians [4].

This content is machine translated SGDV Congress 2022

Scores in chronic inflammatory dermatoses – are they worth the effort?

Whether scores are really necessary to determine the severity of psoriasis and atopic dermatitis is debatable. The expert PD Dr. med. Julia-Tatjana Maul and the expert Prof. Dr. med. phil. nat. Christoph Schlapbach in an Oxford-style debate moderated by Prof. Nikhil Yawalkar, MD, at the AbbVie Satellite Symposium at this year’s SGDV Congress.

This content is machine translated Case Report

Long-term treatment of a patient with severe psoriasis

In the following, dermatologist Dr. Basile Darbellay (MD, MD-PhD) from Orsières describes the case of a patient who has suffered from severe psoriasis for more than 20 years and has been successfully treated with a biological agent for more than three years.

This content is machine translated Indication extension

New therapeutic option for psoriatic arthritis [1].

Psoriatic arthritis (PsA) places a great burden on sufferers and many of them do not respond satisfactorily to the treatments available to date [2]. Now patients with moderate to severe PsA can benefit from an additional effective and tolerable biologic therapy option [1].

This content is machine translated Swiss Derma Day and Allergology & Immunology Update 2022

Modern therapies for atopic dermatitis and psoriasis

Atopic dermatitis and psoriasis often place a physical and psychological burden on sufferers [1, 2]. At this year’s Swiss Derma Day in Lucerne and at the virtual SSAI Allergology & Immunology Update, three experts from Inselspital Bern gave an overview of current treatments, going into more detail about the efficacy and safety of various JAK inhibitors and biologics.

This content is machine translated Review SGDV and EADV Congress 2021

New therapeutic era for patients with atopic dermatitis and psoriasis

Atopic dermatitis and psoriasis are among the most common skin diseases and often impose a great physical, psychological and social burden on those affected [1–4]. A review of the last SGDV and EADV congresses shows that the spectrum of therapy for the two inflammatory dermatoses has greatly expanded thanks to the improved understanding of the pathophysiology.

This content is machine translated Moderate to severe plaque psoriasis

Biologics in head-to-head comparison [1–3]

Biologics have become popular in psoriasis management due to their improved efficacy and advantageous safety profile over conventional therapies [4]. That individual biologics with different target cytokines may differ in efficacy is demonstrated by the results of several head-to-head studies [1–3].

This content is machine translated Interview with Dr. Andreas Pinter Part 2

“No one needs to walk around with psoriasis these days”.

In the second part of his interview, Andreas Pinter, MD, University Hospital Frankfurt/Main, Germany, explains how IL-17 and IL-23 inhibitors differ in the treatment of psoriasis in terms of mechanism of action, clinical trial data, and applicability in practice, and how ambitious therapeutic goals can be better achieved in the future.

This content is machine translated Interview with Andreas Pinter, MD

“Patients want a life without psoriasis”.

In the run-up to his nationwide roadshow from October 6 to 8, 2020, Andreas Pinter, MD, University Hospital Frankfurt/Main, Germany, explained the importance of interleukin (IL)-23 inhibitors for modern psoriasis therapy and reported on his experience with this treatment option as well as on the wishes and expectations of his patients.

This content is machine translated Patient case

“I forgot I had psoriasis.”

With currently available biologics, patients with moderate to severe plaque psoriasis can achieve rapid and durable symptom relief and a sustained improvement in quality of life [1,2]. Using a case report, Ahmad Jalili, MD, illustrates how such ambitious treatment goals became reality for a patient with severe psoriasis vulgaris.

This content is machine translated Interview with Prof. Dr. med. Kristian Reich

“We need to be more sophisticated in psoriasis therapy”

Steady progress has been made in psoriasis therapy, especially with the introduction of new active ingredients. Sustained freedom from symptoms may thus become an achievable treatment goal for many patients with moderate to severe psoriasis (1).

Input your search keywords and press Enter.